Alice Bast is the founder and Executive Director of the National Foundation for Celiac Awareness (NFCA). The Foundation gained official status as a 501(c) (3) nonprofit organization dedicated to finding a cure for celiac disease December 2003. Ms. Bast’s experience in philanthropy, the medical community, marketing and entrepreneurship includes The Hospital of the University of Pennsylvania, SMS, Moburg Medical, Keystone Fundraising and RIK Medical. In addition to Board membership on a number of Celiac Awareness Groups, Ms. Bast is actively involved with the Greater Philadelphia Venture Group, Entrepreneurs Forum, University of Pennsylvania, Children’s Hospital, the Highlands Historical Society and the Wissahickon Watershed Association. She is also on advisory committees for Germantown Academy and The University of Pennsylvania Hospital and a Board Member of the Penllyn Club.
Mr. Bulock joins the management team as a nationally-recognized leader in website development. After founding Passport Express, a leading online travel business specializing in expediting passport and visa procurement (Featured in Jan 2001 Entrepreneur’s Startups magazine), Mr. Bulock co-founded MyHelpDesk, Inc., which was consecutively named to PC Magazine’s 'Top 100 Websites' (1999, 2000) and awarded the 2000 Innovation in Service Award by IT Support News. Mr. Bulock has over 15 years’ IT and business experience, and extensive knowledge of telephone systems, website development, on line marketing, electronic catalogue, IT systems, call center management and data base management.
Richard Bushell was formerly a Vice President for European Finance at GlaxoSmithKline (GSK). He has spent over 20 years in the Pharmaceutical business in various Finance and Commercial roles. He has been involved in negotiating with the UK government on pricing issues on behalf on the Pharmaceutical Industry, a number of product patent defense issues for GSK and competition challenges between the European Competition Commission and GSK. In 1999 he spent 5 months in the US working with SmithKline Beecham’s Chief Operating Officer and the President of Pharmaceuticals. In January 2003, he joined Land Securities, a UK property company, as Director of Finance for the Group. In recent months he has focused on managing a number of private property companies. Mr Bushell is a Fellow of the Chartered Institute of Management Accountants and has a degree in Accountancy and Computer Science from Heriot-Watt University in Edinburgh.
Terry McCarthy has a Bachelor of Science from the University of Newcastle Upon Tyne, UK. He has twenty-years of experience in the field of medical devices, working with a variety of US and International start-up companies beginning clinical studies and early commercialization in Europe, the Middle East and Asia. Mr. McCarthy has worked primarily with companies in the cardiovascular market, typically at the IDE stage in the US and working through the CE-Mark and other regulatory processes internationally. Mr. McCarthy is currently Director for First Clinical and Technical Services Ltd., prior to which he was Director European Clinical & Technical Services at Ventracor Ltd. in Australia. Previously, Mr. McCarthy was with WorldHeart Inc., Myocor Inc., Computer Motion, and Heartport, among others. A graduate of the University of Newcastle-upon-Tyne, he holds a B.Sc. in General Science with concentrations in Physiology and Biochemistry. Mr. McCarthy is Gus Carey’s brother-in-law.
John Wright, the principal of Product & Regulatory Associates, LLC (2002) and PRA Registrations, LLC (2006). Both consulting organization leverage product development activities in the pesticide and pharmaceutical areas to develop and launch new pesticide delivery systems. This includes regulatory support on FIFRA & FQPA projects especially risk assessments under current new EPA guidelines. PRA Registrations, LLC’s main role is to hold third party registration or act as agent for domestic and international clients, especially from PRC. Prior to this, Mr. Wright spent 33 years in various roles of pesticide research, development and registrations for FMC Corporation. His last role was as Director, Global Products & Regulatory Development for FMC’s Specialty Products Business team. He helped grow this business unit from a $1M in 1988 to $150M in 2002 with minimal R&D expense.